Novel thiochroman-4-one derivatives bearing a pyrimidine moiety with potential α-glucosidase inhibitory and antibacterial activities
In this study, a series of novel thiochroman-4-one derivatives functionalized with a pyrimidine moiety were synthesized and fully characterized via1H NMR, 13C NMR, and HRMS. Bioactivity assays demonstrated that compound 5c exhibited the most potent in vitro α-glucosidase inhibition with an IC50 of 15.61 μg/mL, which was superior to that of the positive control acarbose (237.48 μg/mL). Compound 5e showed the strongest in vitro antibacterial activity against Xanthomonas axonopodis pv. citri (Xac) with an EC50 of 10.29 μg/mL, which outperformed both commercial bactericides bismerthiazol (145.65 μg/mL) and thiodiazole copper (227.65 μg/mL). Meanwhile, the molecular docking analysis revealed that compound 5c interacts strongly with the active site of human intestinal α-glucosidase (PDB ID: 3TOP) via several binding interactions, exhibiting a binding energy of −8.8 kcal/mol. Furthermore, in-silico ADMET and drug-likeness predictions indicated that compounds 5c and 5e possessed favorable pharmacokinetic profiles and low toxic risks, satisfying the basic requirements for prospective therapeutic leads. This work establishes a convenient synthetic strategy for pyrimidine-substituted thiochroman-4-one analogues, and provides promising lead candidates for developing dual-functional α-glucosidase inhibitors and antibacterial agents.
Authors
- Xiang Wang (ORCID: https://orcid.org/0000-0002-3380-4115)
- Pei Shan Li (ORCID: https://orcid.org/0000-0001-7276-6337)
- Wenmin Pan
- Tiantian Zhuang
Institutions
- Kaili University (CN)
Publication Details
- Journal
- Phosphorus, sulfur, and silicon and the related elements
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1080/10426507.2026.2764623
- Primary Topic
- Heterocyclic Compound Synthesis and Bioactivity
- Type
- article
- Field-Weighted Citation Impact
- 0.00